Acute ST Segment Elevation Myocardial Infarction Clinical Trial
Official title:
Platelet Function in Resuscitated Patients
Approx. 65% of resuscitated patients at the intensive care unit for internal medicine are due to myocardial infarction. Almost all patients are initially diagnosed and treated in the cath lab. Therapy usually consists of one or more stent implantations. After implantation of a coronary stent, dual platelet inhibition is necessary for 12 months. Insufficient platelet inhibition causes an pronounced increase in risk of stent thrombosis. Therefore, knowledge of the individual platelet function is valuable. Several factors potentially promote a delayed or reduced mode of action of platelet function inhibitors in resuscitated patients: 1. oral administration is impossible and medication needs to be administered via a gastric line. 2. gastric absorption is delayed after resuscitation 3. according to current guidelines patients are treated with therapeutic hypothermia. Including the time of rewarming cooling period is ~48h
Patients after successful resuscitation associated to a myocardial infarction will be included into the study the morning after the index event. Patients get dual platelet inhibition at the discretion of the interventionist. Patients are treated with therapeutic hypothermia according to the local Standard operating procedure for 24h and rewarming is performed within an additional 20h. Platelet function is measured every morning and Aspirin mediated as well as P2Y12 (purinergic G protein-coupled receptors-12)-inhibition mediated platelet function inhibition is recorded. All relevant clinical data including APACHE (Acute Physiology and Chronic Health Evaluation) and SOFA ( Sequential Organ Failure Assessment score) scores are collected. The degree of platelet inhibition over time (7 days) and differences between the three drugs tested will be evaluated by optical aggregometry and by using the commercial VerifyNow test system. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT00697021 -
Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance
|
Phase 3 | |
| Completed |
NCT05949515 -
Retrospective Evaluation of SuperSaturated Oxygen (SSO2) Therapy Clinical Utility
|
||
| Completed |
NCT02828683 -
Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study
|
N/A | |
| Completed |
NCT01986803 -
ABSORB STEMI: the TROFI II Study
|
N/A | |
| Active, not recruiting |
NCT01878344 -
Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention
|
Phase 3 | |
| Withdrawn |
NCT02048085 -
Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
|
Phase 4 | |
| Completed |
NCT04463251 -
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
|
Phase 2 | |
| Active, not recruiting |
NCT02943954 -
FLOW Evaluation to Guide Revascularization in Multi-vessel ST-elevation Myocardial Infarction
|
N/A | |
| Completed |
NCT02298088 -
Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis
|
Phase 3 | |
| Active, not recruiting |
NCT02067091 -
Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct
|
Phase 3 | |
| Completed |
NCT01787110 -
An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction
|
Phase 3 | |
| Recruiting |
NCT03137212 -
Safety and Efficacy of Percutaneous Coronary Intervention Combined With Thrombolysis at Different Time
|
N/A | |
| Not yet recruiting |
NCT05802667 -
A Cohort Study of Correlation Between Mast Cells and Prognosis in Patients With Acute Myocardial Infarction
|
||
| Completed |
NCT04730778 -
Predictive Value of CHA2DS2VASC Score for Contrast-induced Nephropathy After Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction Patients
|